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Gao S, Oh YB, Shah A, Park WH, Chung MJ, Lee YH, Kim
SH. Urotensin II receptor antagonist attenuates monocrotaline-in-
duced cardiac hypertrophy in rats. Am J Physiol Heart Circ Physiol
299: H1782–H1789, 2010. First published September 24, 2010;
doi:10.1152/ajpheart.00438.2010.—Urotensin II (UII) is a vasoactive
peptide with potent cardiovascular effects through a G protein-cou-
pled receptor. Hypoxia stimulates the secretion of UII and atrial
natriuretic peptide (ANP). However, the effect of UII on hypoxia-
induced cardiac hypertrophy is still controversial. The present study
was conducted to determine whether human UII (hUII)-mediated
ANP secretion influences hypoxia-induced cardiac hypertrophy using
in vitro and in vivo models. Hypoxia caused an increase in ANP
secretion and a decrease in atrial contractility in isolated perfused
beating rat atria. hUII (0.01 and 0.1 nM) attenuated hypoxia-induced
ANP secretion without changing the atrial contractility, and the hUII
effect was mediated by the UII receptor signaling involving phospho-
lipase C, inositol 1,3,4 trisphosphate receptor, and protein kinase C. Rats
treated with monocrotaline (MCT, 60 mg/kg) showed right ventricular
hypertrophy with increases in pulmonary arterial pressure and its diam-
eter and plasma levels of UII and ANP that were attenuated by the
pretreatment with an UII receptor antagonist, urantide. An acute admin-
istration of hUII (5 M injection plus 2.5 M infusion for 15 min)
decreased the plasma ANP level in MCT-treated rats but increased the
plasma ANP level in MCT plus urantide-treated and sham-operated rats.
These results suggest that hUII may deteriorate MCT-induced cardiac
hypertrophy mainly through a vasoconstriction of the pulmonary artery
and partly through the suppression of ANP secretion.
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UROTENSIN II (UII) is a neuropeptide originally isolated from
teleost urophysis (12) and has been cloned recently from
humans (1, 13). UII has been identified as a selective ligand of
G protein-coupled receptor termed UII receptor (1, 27, 29).
The stimulation of the UII receptors by UII activates the
Gq-phospholipase C pathway, generating diacylglycerol
(DAG) and inositol 1,3,4-trisphosphate (IP3) that stimulate
protein kinase C (PKC) and Ca2 release from intracellular
stores, respectively (1, 29, 35). Human UII (hUII) is a potent
vasoconstrictor in the artery, which is more potent than that of
endothelin-1 (1, 27). hUII also causes positive inotropy in
human and rat myocardium (21, 34) and mitogenesis in vas-
cular smooth muscle cells (36, 40). However, negative inot-
ropy in rabbit papillary muscle (19) and vasodilation by hUII
have also been reported (17).
Although the expression of the UII receptor is relatively low to
undetectable in normal myocardium, UII and its receptor are
highly expressed in the cardiovascular system and upregulated in
pathological conditions such as ischemic (43, 44) and chronic
hypoxic myocardium (41). An upregulation of the UII receptor
may worsen cardiac hypertrophy (3, 30) and cardiac injury under
ischemia-reperfusion (43). In contrast, the beneficial effects of UII
on decreasing coronary flow and cardiac contractility induced by
ischemia-reperfusion have also been reported (32). Thus the
effects of UII on cardiac function in pathological conditions are
still controversial and remain to be clarified.
Recently, we have shown that hUII stimulates high-pacing
frequency-induced atrial natriuretic peptide (ANP) secretion in
isolated perfused beating atria of normal rats (20). ANP is a
well-known cardiac hormone participating in the regulation of
body fluid and blood pressure (BP) (28). ANP causes natriure-
sis, diuresis, and vasodilation, followed by a reduction in BP
(15). In this study, we investigated the effects of UII on
hypoxia-induced ANP secretion and cardiac hypertrophy using
isolated perfused atria and rats.
MATERIALS AND METHODS
Animals. Male Sprague-Dawley rats, obtained from Orientbio
(Seoungnam, Korea), were housed in a temperature-controlled room
with a 12-h:12-h light-dark cycle. Animals were provided with free
access to standard laboratory chow (5L79 Purina rat and mouse 18%
chow, Charles River, Wilmington, MA) and water. All of the exper-
imental protocols conformed to the National Institutes of Health’s
Guide for the Care and Use of Laboratory Animals (NIH Publication
No. 85-23, Revised 1996) and were approved by the Institutional
Animal Care and Use Committee of the Chonbuk National University.
Preparation of isolated perfused rat atria. Isolated perfused beat-
ing atria were prepared using a method described previously (22). In
brief, hearts were rapidly excised after decapitation, and left atria were
dissected and inserted into a cannulus and ligated by a silk. Cannu-
lated atria were kept in an organ chamber perfused with oxygenated
HEPES-buffered saline at 37.0°C, and the atrium was then paced at
1.2 Hz (duration, 0.4 ms; and voltage, 30 V). The composition of
HEPES-buffered saline was as follows: (in mM) 10 HEPES, 118
NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 25 NaHCO3, and 10 glucose
and 0.1% bovine serum albumin (pH 7.4). Intra-atrial pressure was
recorded using a power lab (ML-820, ADInstruments) via a pressure
transducer (Statham P23Db, Oxnard, CA), and pulse pressure was
obtained from the difference between systolic and diastolic pressure.
The pericardial buffer solution, which contained [3H]inulin (Amer-
sham Biosciences) for measurement of extracellular fluid (ECF)
translocation, was also oxygenated via silicone tube coils inside the
organ chamber. The atrium was perfused for 70 min to stabilize ANP
secretion and to maintain a steady-state [3H]inulin level in the extra-
cellular space. Atrial perfusate was collected five times at 2-min
intervals as a control period, and perfusate was then changed to
HEPES buffer, which was preexposed to N2. Atrial perfusate was
continuously collected for 40 min at 4°C. Partial pressure of O2 (PO2)
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in HEPES buffer was measured during normoxia and hypoxia using
an autoanalyzer (Roche Omni C, Roche Diagnostics).
Experiments were performed with three groups. Group 1 included
control atria exposed to N2-containing HEPES buffer after the control
period (n  10). Group 2 included atria exposed to N2-containing
HEPES buffer and hUII (0.01 nM, n  4; 0.1 nM, n  8) after the
control period in the presence of hUII. Group 3 included atria exposed
to N2-containing HEPES buffer with hUII (0.1 nM) in the presence of
an UII receptor antagonist (urantide, 1 M; n  4), an inhibitor for
phospholipase C (PLC; U-73122, 5 M; n  5), phosphoinositide
3-kinase (PI3K; wortmannin, 0.1 M; n  6), IP3 receptor [2-amin-
oethyldiphenylborinate (2-APB), 10 M; n  7], or PKC
(GF109203x, 1 M; n  5) during hypoxia. The antagonist or
inhibitor was pretreated from 30 min before starting the sample
collection, and N2-containing HEPES buffer with hUII (0.1 nM) was
then perfused after the control period. For an evaluation of the effects
of inhibitor itself, urantide or the inhibitor was pretreated from 30 min
before starting the perfusate collection and N2-containing HEPES
buffer was then perfused (n  4–7).
Chronic infusion of urantide in monocrotaline-treated rats. Male
rats weighing 160–180 g were anesthetized by an intraperitoneal injec-
tion of a mixture of ketamine and xylazine (9:1, 2 ml/kg). Before
implantation, a mini-osmotic pump (Alzet 2002, Cupertino, CA) was
filled with urantide solution and kept in autoclaved saline (37°C) for 8 h.
After a transverse incision in the scapular region (1.0–1.5 cm), the
osmotic pump was implanted subcutaneously between the scapula and
urantide was infused for 14 days at a dose of 30 g·kg1·day1.
Sham-operated rats were anesthetized and operated with the same pro-
cedure, except for the implantation of osmotic pump (37). Two days after
implantation, the rats were given a single subcutaneous injection of 60
mg/kg monocrotaline (MCT) or vehicle. The rats were euthanized at 2 wk
by decapitation, and the blood was collected. Body weight and right
ventricle, left ventricle plus septum, left atrium, and right atrium weights
were measured. Tissue and plasma were stored at 70°C until assayed.
Acute intravenous infusion of hUII in MCT-treated rats. Male
Sprague-Dawley rats were given a single subcutaneous injection of 60
mg/kg MCT in the absence and presence of urantide or vehicle (26).
After 2 wk, the rats were anesthetized by an intraperitoneal injection
of a mixture of ketamine and xylazine (9:1, 2 ml/kg). Body temper-
ature was maintained at 36 to 37°C using a heating pad. After a
midline incision in the neck, the jugular vein and carotid artery were
carefully dissected, cannulated with polyethylene tube (PE-50), and
secured with ligation. The cannula in the jugular vein was connected
to a peristaltic pump (Minipuls 2 Gilson, Villiers le Bel, France) for
infusion of vehicle (0.9% NaCl) and hUII in 0.9% NaCl at a constant
rate of 60 l/min and the cannula in the carotid artery to the pressure
Fig. 1. A: effects of hypoxia on pulse pres-
sure (a), extracellular fluid (ECF) transloca-
tion (b), atrial natriuretic peptide (ANP) se-
cretion (c), and ANP concentration (Conc)
(d) as a function of time in isolated perfused
atria beating at 1.2 Hz in the absence and
presence of human urotensin II (UII; 0.01
and 0.1 nM). Perfusate was collected every 2
min as a control at 1.2 Hz for 10 min, and
then hypoxia was applied by changing oxy-
genated HEPES buffer to N2-containing
buffer. Perfusate was continuously collected
for 40 min. Atria were exposed to UII simul-
taneously with hypoxia. Arrow indicates the
exposure time to hypoxia. B: relative percent
changes in pulse pressure (a), ECF translo-
cation (b), ANP secretion (c), ANP Conc (d)
by hypoxia in the absence and presence of
different concentrations of UII. Values are
expressed as percent changes of the mean of
the last 5 experimental values (fraction no.
21–25) exposed to UII, compared with the
mean of control values (fraction no. 1–5). Val-
ues are expressed as means  SE. Cont, con-
trol hypoxia group. *P 0.05 and **P 0.01
vs. Cont.
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transducer (Statham P23Db) (20). BP and heart rate (HR) were
recorded using a power lab (ML-820, ADInstruments) via the pressure
transducer. Animals were stabilized for 10 min with 0.9% saline
infusion, and blood (800 l) was collected via the carotid artery. hUII
(5 M) was injected followed by subsequent infusion (2.5 M)
through the jugular vein for 15 min. Blood was collected at 15 and 20
min after the start of hUII infusion. Blood was centrifuged at 10,000
g at 4°C for 10 min, and plasma was kept at 70°C until assay.
Measurement of right ventricular and pulmonary arterial pressure.
Both right ventricular and pulmonary arterial pressures were mea-
sured by catheterization through right heart. In brief, rats were
anesthetized by an intraperitoneal injection of a mixture of ketamine
and xylazine (9:1, 2 ml/kg). The PE tube with a curl at the end of tube
was cannulated into the jugular vein and reached the main pulmonary
artery via the right ventricle while tracing pressure change onto a
power lab (ML-820, ADInstruments) using pressure transducer
(Statham P23Kb) connected with PE tube. After bleeding, the left
ventricle and abdominal aorta were cut and 10 ml phosphate-buffered
saline (0.01 M) was injected into the pulmonary artery through the
cannula. Both lungs were isolated and stored in saline at 4°C for
hematoxylin and eosin staining.
Lung histology and morphometric analysis. Lung sections (6 m)
were stained with hematoxylin and eosin and examined in a blind
fashion using a light microscope. Images of arteries were captured
with a microscope digital camera, and the internal and external
diameter of the pulmonary arteries was measured. At least 30 arteries
of comparable size (50–100 m in diameter) per rat from each group
were evaluated (n  3). The percentage of medial thickness was
determined by dividing the area occupied by the medial muscular
layer by the total cross-sectional area of the artery (11).
Radioimmunoassay of ANP concentrations. The ANPs in plasma
were extracted using a Sep-Pak C18 cartridge (Waters Associates,
Milford, MA) (7), and the concentration of ANP in perfusate and
plasma was measured by a specific radioimmunoassay (RIA) as
described previously (9, 10). The secreted amount of ANP in perfus-
ate was expressed in nanograms per minute per gram of atrial tissue.
We previously reported a two-step sequential mechanism of ANP
secretion; first, the stored ANP is released from atrial myocytes into
interstitial space by atrial distension, and second, the released ANP is
secreted into the atrial lumen, concomitant with translocation of ECF
by atrial contraction (6, 8). Therefore, the molar concentration of ANP
release in the interstitium was calculated as follows:
Fig. 2. A: modification of effects of UII on hypoxia-induced changes in pulse pressure (a), ECF translocation (b), ANP secretion (c), and ANP Conc (d) depicted
as the relative percent changes in the presence of inhibitor for UII receptor and downstream signaling molecules. Antagonist or inhibitors [1 M urantide (B),
5 M U-73122 (C), 1 M 2-aminoethyldiphenylborinate (2-APB; D), 1 M GF-109203x (E), and 0.1 M wortmannin (F)] was pretreated from 30 min before
the start of sample collection. After 10-min control period, atria were exposed to N2-containing buffer and UII (0.1 nM). Cont, control group in the absence of
inhibitor. *P  0.05 and ** P  0.01; #P  0.05 vs. control group. Legend is the same as in Fig. 1.
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ANP concentration M 
ANP pg · min1 · g1
ECF translocation l · min1 · g13,090
The denominator 3,090 indicates the molecular mass of ANP1–28 (in
Da) since the ANP secreted was found to be the processed ANP (6).
Measurement of ECF translocation. The radioactivity of [3H]inulin
in atrial perfusate was measured by a liquid scintillation counter
(Tris-Carb 23-TR; A Packard Bioscience, Downers Grove, IL) (6, 8).
The amount of ECF translocated (in l·min1·g1) through the atrial
wall was calculated as follows:
Total radioactivity in perfusate cpm/min 1,000
radioactivity in pericardial reservoir cpm/l atrial wet weight mg
Measurement of UII concentration. UII in perfusate and plasma
was extracted as the same method as ANP using a Sep-Pak C18
cartridge (Waters Associates) (7). The recovery rate was 81.5 2.4%
(n  6). The UII concentration was measured using a rat UII RIA kit
(Phoenix Pharmaceuticals, Bulingame, CA).
Real time-PCR. Total RNA was extracted from rat heart tissue using
TRIzol reagent (Invitrogen, Carlsbad, CA), and reverse transcription was
performed using Superscript II and 18-mers Oligo-dT (Invitrogen). Spe-
cific primers were designed using primer express software (Applied
Biosystems, Carlsbad, CA), and their primer sequences were as follows:
rat UII (accession no. NM_019160.1), 5=-GGCGAGAACCAGGAAA-
CAAC-3= (forward) and 5=-CAAATGCAGTACTTCCAGAAGCA-3=
(reverse); rat UII receptor (accession no. NM_020537.1), 5=-
ACAGATCCCAGCTCCCTGAA-3= (forward) and 5=-GAGCACTGC-
CCCGATGAC-3= (reverse); rat ANP (accession no. NM_012612.2),
5=-CCGGTACCGAAGATAACAGC-3= (forward) and 5=-CTCCAG-
GAGGGTATTCACCA-3= (reverse); and rat actin (accession no.
NM_031144.2), 5=-ACCAGTTCGCCATGGATGAC-3= (forward), and
5=-TGCCGGAGCCGTTGTC-3= (reverse).
Real-time PCR reaction contained in a final volume of 10 l, 10 ng
of reverse transcribed total RNA, 200 nM of forward and reverse
primers, and 2 	 PCR master mix. PCR reaction was carried out in
Fig. 3. Changes of UII level in perfusate in
terms of time in control normoxic group (A)
and in experimental hypoxic group (B). UII
level was measured in perfusates collected
from the 5 control periods (fraction no. 1–5)
and last 5 experimental periods (fraction no.
21–25). C: values are expressed as the relative
percent changes of the mean of experimental
values, compared with means of control val-
ues. Values are means  SE. **P  0.01 vs.
corresponding group.
Fig. 4. Changes in right ventricular (RV)
weight (RVW; A); expression of UII (B), UII
receptor (URT; C), and ANP mRNA (D) in
RV; and plasma concentrations of UII (E)
and ANP (F) in monocrotaline-treated
(MCT) rats in the absence and presence of
urantide. Rats were given a single subcuta-
neous injection of 60 mg/kg MCT or vehicle.
Two days before MCT injection, urantide or
vehicle started to infuse using osmotic
pump. Rats were euthanized 2 wk after MCT
injection. UT, urantide-treated rats; RVW/
BW, ratio of right ventricular weight to body
weight; UII/actin, URT/actin, and ANP/actin
mRNA, relative expression of UII, UII re-
ceptor, and ANP mRNA to actin mRNA in
RV, respectively. *P 0.05 and **P 0.01
vs. control rats.
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384-well plates using the ABI Prism 7900HT Sequence Detection
System (Applied Biosystems). All reactions were done in triplicate.
Statistical analysis. Results are presented as means  SE. Statis-
tical significance of differences was assessed using ANOVA followed
by Bonferroni multiple comparison test. Student’s t-test was also
used. The critical level of significance was set at P  0.05.
RESULTS
Effects of hUII on hypoxia-induced atrial contractility and
ANP secretion. After a collection of five samples as a control,
the buffer was changed to N2-preexposed HEPES buffer. PO2
in control buffer was 181.7  2.9 mmHg, and PO2 during
hypoxic condition was 49.83  4.8 mmHg (n  6). Hypoxia
decreased atrial contractility (Fig. 1A,a), and ECF translocation
remained unchanged (Fig. 1A,b). In contrast, hypoxia markedly
increased ANP secretion and concentration (Fig. 1A, c and d).
When atria were treated with hUII at a dose of 0.01 and 0.1
nM, the hypoxia-induced decrease of atrial contractility and
ECF translocation were virtually unaffected. However, the
hypoxia-induced ANP secretion and concentration were re-
duced. Figure 1B shows a relative percent change of the mean
of the first five control values during normoxia and the last five
experimental values during hypoxia in the absence or presence
of hUII. Hypoxia increased ANP secretion by 320%. Pretreat-
ment with hUII (0.1 nM) attenuated the hypoxia-induced ANP
secretion by 130% (Fig. 1B,c).
Effects of hUII on hypoxia-induced ANP secretion in the
presence of receptor antagonist or inhibitor of signaling
modulators. Since it has been shown that the stimulation of the
UII receptor by UII activates Gq-phospholipase C, produc-
ing two second messengers, DAG and IP3, which stimulate
PKC and Ca2 release from intracellular Ca2 stores, respec-
tively (1, 29, 35), we examined whether these signaling mol-
ecules regulate hypoxia-induced ANP secretion. Atria were
pretreated with a UII receptor antagonist or inhibitors of these
signaling molecules. As expected, an antagonist of UII receptor
urantide (0.1 M) blocked the suppressive effect of UII on the
hypoxia-induced increase of ANP secretion and concentration
(Fig. 2B, c and d) without affecting pulse pressure and ECF
translocation. Pretreatment with U-73122 (PLC inhibitor, 5
M) or 2-APB (IP3 receptor inhibitor, 10 M) attenuated the
suppressive effect of hUII on hypoxia-induced ANP secretion
and concentration (Fig. 2, C and D). The PKC inhibitor
GF-109203x (1 M) slightly attenuated the effect of hUII on
the ANP secretion and concentration but without statistical
significance (Fig. 1E). In addition, PI3K has been known to be
activated in hypoxia and oxidative stress (18). An involvement
of this kinase in hUII signaling was examined using wortman-
nin, an inhibitor of PI3K. Pretreatment with wortmannin (0.1
M) did not block the hUII effect on hypoxia-induced ANP
secretion (Fig. 2F, c and d), whereas the hUII/hypoxia-induced
pulse pressure was decreased (Fig. 2F,a). U-73122 or 2-APB
alone decreased hypoxia-induced ANP secretion and concen-
tration, and wortmannin alone markedly decreased ECF trans-
location during hypoxia. Other inhibitors did not affect hy-
poxia-induced changes in these atrial parameters (Fig. 2).
To determine whether an acute exposure of atria to hypoxia
increases the UII level, the UII level in perfusate was measured
before and during hypoxia. The perfusate was collected during
the first five control periods and the last five experimental
periods, and UII was extracted and then assayed. The UII level in
the perfusate of normoxic atria was decreased by 40% (Fig. 3, A
Fig. 5. A and B: changes in systolic RV pressure (RVP) and pulmonary arterial pressure (PAP) in control, MCT-treated, and MCT plus UT-treated rats.
C: relationship between RVP and PAP. D: representative hematoxylin and eosin-stained peripheral lung sections from control and MCT-treated and MCT plus
UT-treated rats. Pulmonary artery is indicated with arrows. Total magnification, 	400. E: quantitative morphological analysis of percentage of wall thickness
of pulmonary artery. *P  0.05 and **P  0.01 vs. control group.
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and C). In contrast, the UII level in perfusate of hypoxic atria
was increased by 20% (Fig. 3, B and C).
Effects of urantide on MCT-induced cardiac hypertrophy.
The above in vitro data indicated that UII suppresses hypoxia-
induced ANP secretion, and ANP plays a critical role in
regulating BP (15, 28). To examine the effects of hypoxia and
UII on cardiac hypertrophy and ANP secretion, MCT was
injected into rats to induce hypoxia in the absence or presence
of urantide. The treatment of rats with MCT increased the ratio
of right ventricle weight to body weight (Fig. 4A) and the
expressions of UII (Fig. 4B), UII receptor (Fig. 4C), and ANP
mRNAs (Fig. 4D) in the right ventricle compared with those in
control rats. Plasma levels of UII (Fig. 4E) and ANP (Fig. 4F)
were also increased substantially compared with the levels in
control rats. The treatment of MCT-injected rats with urantide
for 2 wk significantly attenuated ventricular hypertrophy and
decreased the expression of ANP mRNA and the plasma UII
and ANP levels. However, the expression of UII and URT
mRNAs in the right ventricle was slightly decreased but
without statistical significance (Fig. 4, B and C).
MCT-treated rats also showed higher right ventricular pres-
sure (Fig. 5A) and pulmonary arterial pressure (Fig. 5B) than
those in control rats. Pretreatment with urantide prevented the
MCT-induced increase of right ventricular pressure and pul-
monary arterial pressure. There was a positive correlation
between right ventricular pressure and pulmonary arterial pres-
sure (Fig. 5C) (y 0.56x 2.32, r2  0.85, P 0.01). Figure
5D shows the representative hematoxylin and eosin-stained
peripheral lung sections from control normoxic, MCT-treated,
and MCT plus urantide-treated rats. The percentage of wall
thickness of the pulmonary arteries was greater in MCT-treated
rats than that of control rats (Fig. 5E). Pretreatment with
urantide attenuated wall thickening of the pulmonary arteries in
MCT-treated rats.
Acute intravenous infusion of hUII in MCT-treated rats. To
determine the acute effect of hUII on plasma ANP level and the
hemodynamics in MCT-treated rats, 2.5 M hUII was infused
for 15 min after 5 M bolus injection to anesthetized rats in the
absence or presence of urantide. The infusion of hUII caused
increases in mean arterial pressure, HR, and pulse pressure in
MCT-treated rats, which were similar to control rats (Fig. 6A).
With urantide-treated rats, the infusion of hUII caused in-
creases in mean arterial pressure and pulse pressure but not HR
(Fig. 6B). The infusion of hUII decreased the plasma concen-
tration of ANP in MCT-treated rats (Fig. 6A,d). In contrast,
hUII increased the plasma concentration of ANP in control and
MCT plus urantide-treated rats (Fig. 6B,d).
DISCUSSION
In this study, we have examined the roles of UII in ANP
secretion under hypoxic condition and in the pathogenesis of
hypoxia-induced cardiac hypertrophy. The results revealed that
UII suppresses ANP secretion from hypoxic atria via the UII
receptor/PLC/IP3 pathway. The administration of MCT caused
right ventricular hypertrophy and increased pulmonary arterial
pressure with an increased plasma UII and ANP levels that
were attenuated by pretreatment with a UII receptor antagonist.
The acute infusion of hUII also reduced the plasma ANP level
in MCT-treated rats but not in MCT plus urantide rats. These
results suggest that UII may deteriorate MCT-induced cardiac
hypertrophy mainly through the vasoconstriction of the pul-
monary artery and partly through the suppression of ANP
secretion.
Studies have shown that the plasma concentration of UII is
elevated in various cardiovascular disorders (31, 39) and that
the UII receptor is upregulated in ischemic (43) and chronic
hypoxic myocardium (41). Hypoxia also stimulates UII secre-
tion both in vitro and in vivo (32, 41). The present study
showed that the exposure of isolated atria to hypoxia for 40
min stimulated UII secretion even though the amount of UII
was relatively low. MCT-treated rats, an in vivo hypoxic
model, showed an increased expression of UII and UII receptor
mRNAs in the right ventricle and a high-plasma UII level
compared with those in control rats. Thus our findings provide
additional information on the regulation of UII and the expres-
sion of the UII receptor in hypoxia-induced cardiac hypertro-
phy.
Fig. 6. Changes in mean arterial pressure (MAP; a), heart rate (HR; b), pulse
pressure (c), and plasma ANP level (d) by acute infusion of UII in control,
MCT-treated (A), and MCT plus UT-treated (B) rats. Human UII (5 M) was
injected intravenously and subsequently infused at a dose of 2.5 M for 15 min
(hatched bar). *P  0.05 vs. control value; #P  0.05 vs. control group.
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ANP plays an important role in the normal adaptation to
hypoxia and in the pathogenesis of acute and chronic pulmo-
nary hypertension (5, 23). Hypoxia is a well-known stimulus
for ANP secretion (5, 15, 23, 38). A hypoxia-induced increase
of plasma ANP causes a vasodilation of pulmonary artery and
attenuates hypoxia-induced pulmonary hypertension (2). In the
present study, we have found that treatment of isolated atria
with hUII inhibited hypoxia-induced ANP secretion and that
the infusion of hUII into MCT-treated rats decreased the
plasma ANP level. Our data are in good agreement with the
report showing that rat UII inhibits ANP secretion induced by
cardiac ischemia-reperfusion in Langendorff preparations (32).
In contrast, we have previously reported that a low concentra-
tion of UII stimulates ANP secretion in normal atria paced with
high frequency (20). Taken together, these observations sug-
gest that UII may differently regulate ANP secretion in patho-
logical versus physiological conditions. Since the mechanism
of differential regulation of ANP secretion by UII is com-
pletely unknown, further studies are needed to address this
issue.
Stimulation of UII receptors by UII activates Gq-phospho-
lipase C, generating DAG and IP3, which stimulate PKC and
IP3 receptors (1, 29, 35). Our results showed that hypoxia-
induced ANP secretion is mediated by the stimulation of the
UII receptor/PLC/IP3 pathway. Thus urantide reversed UII-
mediated inhibition of hypoxia-induced ANP secretion, and the
treatment of perfused beating atria with a PLC inhibitor or an
IP3 receptor inhibitor alone decreased hypoxia-induced ANP
secretion. However, the inhibitors for PI3K and PKC tended to
decrease hypoxia-induced ANP secretion but without statistical
significance. These results suggest that hypoxia induces the
stimulation of PLC and IP3 receptor, and these signaling
molecules play a critical role in ANP secretion and concentra-
tion.
It is of interest to observe that hypoxia-induced ANP secre-
tion in isolated beating atria was inhibited by a treatment with
hUII but not by urantide, whereas a hypoxia-induced increase
of the plasma ANP level as well as the expression in
MCT-treated rats was inhibited by urantide. It has been
suggested that a decreased plasma ANP level causes vaso-
constriction of the pulmonary artery and worsens pulmonary
hypertension (2). Therefore, it is possible that a high level of
plasma UII observed in MCT-treated rats may suppress
hypoxia-induced ANP secretion, followed by deteriorating
cardiac hypertrophy. However, the plasma ANP level was
higher in MCT-treated rats than that in urantide-treated rats.
Ventricular ANP synthesis is reactivated by hypertrophy and
then secreted constitutively into the circulation (15). Therefore,
a high level of plasma ANP in MCT-treated rats may be due to
the reactivation of ANP synthesis in hypertrophied ventricle. In
fact, the level of ANP mRNA in the left ventricle of MCT-
treated rats was increased, and the treatment with urantide
reduced the levels of ANP mRNA and plasma ANP as well as
ventricular hypertrophy, suggesting an important role of UII in
the pathogenesis of the heart.
In addition, hUII has been shown to promote pulmonary
vascular remodeling (16), and the vasoconstrictor response to
UII is increased by pulmonary hypertension (14). Studies have
also suggested that hypoxia causes pulmonary hypertension by
UII-dependent activation of NADPH oxidase in the pulmonary
vascular wall and that UII worsens the injury of the hearts
under ischemia-reperfusion (4, 33, 43). MCT is known to cause
an epithelial proliferation of small pulmonary arteries, fol-
lowed by pulmonary hypertension and congestive heart failure
(25). In our study, MCT-treated rats showed right ventricular
hypertrophy, high pressure, and wall thickening of the pulmo-
nary artery. These MCT-induced pathological features were
attenuated by the treatment with urantide. Taken together,
these findings demonstrate that hypoxia induces cardiac hyper-
trophy, at least in part, through wall thickening of the pulmo-
nary artery and that the antagonists for the UII receptor may
protect hypoxia-induced cardiac hypertrophy.
In conclusion, our results have shown that UII may deteri-
orate hypoxia-induced cardiac hypertrophy mainly through
vasoconstriction of the pulmonary artery and partly through the
suppression of ANP secretion. These findings suggesting that a
blockade of the UT receptor improved hypoxia-induced car-
diac hypertrophy.
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